Print this page    •   Back to Web version of article

International News
British Columbia Expands Coverage Under PharmaCare Plan for New Drug for Hepatitis C

March 30, 2012

British Columbia's government has announced that its PharmaCare plan will begin providing boceprevir for hepatitis C patients who meet certain eligibility requirements. Known by the trade names Victrelis and Victrelis Triple, the medication is used in combination with other drugs and has been shown to boost cure rates by up to 25 percent. Boceprevir gained Health Canada approval last summer. Providing the drug will cost up to $50 million (US $50 million) during the next three years, the government said.

Back to other news for March 2012

Excerpted from:
Canadian Press

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.